source
- Argenx deepens immuno expertise with $2.2B Forte Biosciences buyThe star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
- Study shows drug development and reimbursement timelines align across four major marketsResearchers published a cross‑sectional analysis in JAMA Health Forum examining how long it takes for a drug to move from the start of clinical trials to receiving reimbursement approval. The anal…